EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)
Status:
Active, not recruiting
Trial end date:
2022-12-21
Target enrollment:
Participant gender:
Summary
The primary aim of the study is to investigate the effect of empagliflozin on kidney disease
progression or cardiovascular death versus placebo on top of standard of care in patients
with pre-existing chronic kidney disease
Phase:
Phase 3
Details
Lead Sponsor:
Boehringer Ingelheim
Collaborators:
Eli Lilly and Company Medical Research Council Population Health Research Unit, CTSU, University of Oxford (academic lead)